Shots:

• The P-lll DAPA-CKD study involves the assessing of Farxiga (qd- 10 mg) + SOC vs PBO in 4304 patients with CKD stages 2-4 and elevated urinary albumin excretion- with/ out T2D
• Results of subgroup analysis : RRR & ARR (5.8% & 37%) for patients whose CKD was primarily driven by diabetic kidney disease; (25% & 2.2%) for high B.P.; (57% & 7.5%) for glomerulonephritis; (42% & 5.0%) for CKD of other or unknown causes (ARR = 5.0%) respectively. Also showed reduction in in all-cause mortality as secondary outcome
• Farxiga (PO- qd) is a first-in-class SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monotherapy & combination regimen as an adjunct to diet and exercise to improve glycemic control and has received FDA’s BTD & CHMP’s recommendation in Oct’2020

 ­ Ref: AstraZeneca | Image: NPR